Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Allbirds IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Allbirds Inc trades at $2.6 (market cap $22.68M), while Ginkgo Bioworks Holdings Inc trades at $7.55 (market cap $515.15M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 22.7× Allbirds Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIRDDNA
Market Cap
$22.68M$515.15M
Sector
Consumer CyclicalHealth
52-Week High
$16.99$16.14
52-Week Low
$2.21$5.48
Enterprise Value
$41.54M$617.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $2.53, up 5.42% with a bullish technical signal despite mixed earnings. The company completed a strategic pivot from footwear to AI infrastructure in June 2026, appointing former AWS executive Nadia Carlsten as CEO. While revenue declined to $152M in 2025 with a -53.4% net margin, the P/S ratio of 0.15 suggests potential undervaluation relative to AI sector peers.

The outlook hinges on successful execution of the AI infrastructure strategy, though significant execution risks remain given negative cash flows and lack of profitability. Analyst consensus shows cautious optimism with 21% buy ratings amid high institutional hold positions. Near-term catalysts include new board appointments and AI business development progress.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA